RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

NCT ID: NCT03699956

Last Updated: 2024-03-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-12-24
• Study Completion Date: 2024-03-01

Brief Summary

This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.

Detailed Description

Small cell cancer (SCC), which mostly arises in the lungs but also in other parts of the body as well such as the prostate and the intestines, is one of the most aggressive forms of cancer; in fact, SCC is so aggressive that in 2012 Congress designated it a recalcitrant or difficult-to-treat cancer, along with pancreatic cancer and glioblastoma or GBM, a primary tumor of the brain, which share the terrible "distinction" of having a 5 year survival rate less than 50%.

One of the main reasons that SCC is so recalcitrant or difficult-to-treat has to do with the development of resistance. Almost all cancers (and SCC is no exception) are treated according to lines of therapy. A line of therapy is a particular course of treatment or treatment regimen. So, in SCC, the first line of treatment is a platinum doublet, with the word doublet meaning two, and consists of the double chemotherapy regimen of cisplatin or carboplatin + etoposide. Most patients initially respond well to the platinum doublet but unavoidably, as a matter of course, resistance to treatment develops and, with that development, a new treatment in second line is started. The same pattern is followed in later lines of therapy: resistance in second line leads to the start of another treatment in 3rd line, and with resistance in 3rd line, which is, unfortunately, just as inevitable, and usually happens even sooner, since the later the line of therapy the more aggressive the tumor, a 4th line treatment is started and so on and so forth until, eventually, no lines of treatment are left. The implicit or unwritten rule in cancer therapy is that once resistance occurs on a particular treatment that same treatment is never reintroduced or restarted.

RRx-001 is a form of immunotherapy that has the potential to overturn this unwritten rule by sensitizing tumors, in other words, by making them more sensitive to the platinum doublet that they received in first line. This is very important because, as previously stated, the platinum doublet is usually the most effective therapy, so it is a benefit to patients if sensitivity to the platinum doublet is restored or increased (even in cases where no response ever occurred) and now they respond as if they were in 1st line rather than in 3rd line or beyond.

In this study, which is called REPLATINUM, because patients will be reintroduced to or restarted on a platinum doublet, there is a 50% chance of receiving either RRx-001 + platinum doublet in Arm 1 or a platinum doublet without RRx-001 in Arm 2. However, patients in arm 2 whose cancer progresses or gets worse (as determined by imaging scans), have the opportunity to "cross-over" to Arm 1 and receive RRx-001 + platinum doublet until such time as their cancer progresses. In this way, all patients, even those on Arm 2, are potentially eligible to be treated with RRx-001.

Conditions

Carcinoma, Small Cell Lung

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1

RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks

Cisplatin/carboplatin plus etoposide (up to 4 cycles):

1. Cisplatin or Carboplatin:

1. Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR

2. Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks

2. Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks

Group Type: EXPERIMENTAL

RRx-001 + eLOOP Device

Intervention Type: COMBINATION_PRODUCT

RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device

Cisplatin/carboplatin plus etoposide

Intervention Type: DRUG

Standard of care platinum doublet chemotherapy

Arm 2

Cisplatin/carboplatin plus etoposide (up to 4 cycles):

1. Cisplatin or Carboplatin:

1. Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR

2. Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks

2. Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks

Group Type: ACTIVE_COMPARATOR

Cisplatin/carboplatin plus etoposide

Intervention Type: DRUG

Standard of care platinum doublet chemotherapy

Interventions

RRx-001 + eLOOP Device

RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device

Intervention Type: COMBINATION_PRODUCT

Cisplatin/carboplatin plus etoposide

Standard of care platinum doublet chemotherapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 and < 80 years

2. Prior platinum treatment is required

3. Prior treatment with a checkpoint inhibitor is required unless contraindicated. Maintenance with a checkpoint inhibitor is NOT required

4. Patient must have received at least 2 prior lines of therapy

5. Biopsy confirmation of small cell lung cancer

6. Capable of providing informed consent and complying with trial procedures

7. Measurable disease by RECIST 1.1. Measurable lesions will be confirmed by imaging (CT scan)

8. PS 0-1

Exclusion Criteria

1. Symptomatic central nervous system metastases or neurologically unstable patients that are on increasing steroid dose.

2. The presence of another primary malignancy (excluding in situ of the cervix or basal carcinoma of the skin)

3. Treatment of SCLC with any antineoplastic agent with the exception of steroids.

4. Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, Hepatitis B, Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, certain heart conditions, or mental illness/social situations that would limit compliance with study requirements.

5. History of an allergic reaction to previously received platinum-based regimen, or history of having to discontinue previously received platinum-based regimen secondary to toxicity (excluding hematologic toxicity)

6. Any clinical laboratory findings, which give reasonable suspicion of a disease or condition that contraindicates the use of any study medication or renders the patient at high risk from treatment

7. Uncontrolled or symptomatic pleural or pericardial effusion

8. Pregnant or nursing. There is a potential for congenital abnormalities and for this regimen to harm nursing infants

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

EpicentRx, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bryan Oronsky, MD, PhD

Role: STUDY_DIRECTOR

EpicentRx, Inc.

Locations

Centura Health Research Center

Denver, Colorado, United States

Mid Florida Hematology and Oncology Center

Orange City, Florida, United States

AdventHealth Hematology and Oncology

Orlando, Florida, United States

H. Lee Moffitt Cancer Center & Research Institute, Inc.

Tampa, Florida, United States

Rush University Medical Center

Chicago, Illinois, United States

Cotton O'Neil Clinical Research Center.Hematology & Oncology

Topeka, Kansas, United States

The University of Kansas Cancer Center

Westwood, Kansas, United States

Norton Cancer Institute, Norton Healthcare Pavilion

Louisville, Kentucky, United States

University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center

Baltimore, Maryland, United States

University of Mississippi Medical Center

Jackson, Mississippi, United States

Washington University School of Medicine - Siteman Cancer Center

St Louis, Missouri, United States

Oncology Hematology West PC dba Nebraska Cancer Specialists

Omaha, Nebraska, United States

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

Tennessee Cancer Specialists

Knoxville, Tennessee, United States

Millennium Oncology

Houston, Texas, United States

HOPE Cancer Center of East Texas

Tyler, Texas, United States

Utah Cancer Specialist

Salt Lake City, Utah, United States

Countries

United States

References

Jayabalan N, Oronsky B, Cabrales P, Reid T, Caroen S, Johnson AM, Birch NA, O'Sullivan JD, Gordon R. A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation. Drugs. 2023 Apr;83(5):389-402. doi: 10.1007/s40265-023-01838-z. Epub 2023 Mar 15.

Reference Type: DERIVED

PMID: 36920652 (View on PubMed)

Oronsky B, Reid TR, Larson C, Caroen S, Quinn M, Burbano E, Varner G, Thilagar B, Brown B, Coyle A, Ferry L, Abrouk N, Oronsky A, Scribner CL, Carter CA. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncol. 2019 Oct;15(30):3427-3433. doi: 10.2217/fon-2019-0317. Epub 2019 Sep 11.

Reference Type: DERIVED

PMID: 31509028 (View on PubMed)

Other Identifiers

RRx001-33

Identifier Type: -

Identifier Source: org_study_id